Diligence memo · auto-generated · as of July 2, 2026
RedShift BioAnalytics, Inc.
RedShift BioAnalytics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
RedShift BioAnalytics, Inc. operates in Other Technology, based in Boxborough.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
RedShift BioAnalytics, Inc. has raised $61M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2018-09-21.
Most recent recorded round closed around 2025-06-12.
Valuation (modeled)modeled
Provath models RedShift BioAnalytics, Inc. at approximately $32M (range $14M–$47M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.31× the median modeled value of Series B Other Technology companies in 2025–2027 (193 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 13 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Other Technology peers (21292 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: Proscia Inc., Creditly Corp., Enbalg Group Corp, Lumana Inc., ProrataAI, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.